<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

The Cancer Letter

Zaltrap Shows Improvement in Survival In Stage IV Metastatic Colorectal Cancer

Trial: Decitabine Improves Survival in Myeloid Leukemia

Gleevec For KIT-positive Tumors Shows 92 Percent Overall Survival

VEGF Levels Can Predict Tumor’s Resistance to Avastin

More Patients Get Screened, Colorectal Death Rates Drop

Revlimid Shows 91 Percent Response in Non-Hodgkin’s

Revlimid Also Demonstrates Response in Mantle Cell

FPD-R Regimen Well-Tolerated, With 63 Percent Complete Response

Overall Cancer Mortality Rates Higher For Men Than Women

New Model For Risk Assessment Includes Alcohol, Exercise, Weight